Regressive Autism Spectrum Disorder: High Levels of Total Secreted Amyloid Precursor Protein and Secreted Amyloid Precursor Protein-α in Plasma

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by social communication difficulties, repetitive behaviors, and parochial interests. Individuals with regressive ASD (RA), a unique subtype, have poor outcomes. Moreover, there are currently no validated blood-based biomarkers for ASD, hindering early diagnosis and treatment. This study was the first to examine plasma levels of total secreted amyloid precursor protein (sAPPtotal), secreted amyloid precursor protein-alpha (sAPP alpha), and secreted amyloid precursor protein-beta (sAPP beta) in children diagnosed with RA (n = 23) and compare them with the levels in age-matched children with non-regressive ASD (NRA) (n = 23) and typically developing (TD) controls (n = 23). We found that sAPPtotal and sAPP alpha levels were significantly higher in children with RA than in children with NRA or in TD controls. In contrast, no difference was observed in sAPP beta levels. In conclusion, increased plasma levels of sAPPtotal and sAPP alpha may be valuable biomarkers for the early identification of ASD regression. Prospective studies will be conducted using a larger sample to further investigate these differences.

Automated summary

This study investigated plasma biomarkers in individuals with regressive autism spectrum disorder (RA) and found significantly elevated levels of sAPPtotal and sAPP alpha, which may serve as potential biomarkers for early identification of autism regression.